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Introduction
Neurodegenerative diseases, such as Alzheimer's disease (AD), 
Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS); 
Multiple Sclerosis (MS); Huntington's disease (HD); Machado-
Joseph disease; Amyloid Polyneuropathy Family are characterized by 
a progressive loss of anatomically or physiologically related neuronal 
systems (cognitive function, dementia, and problems with movements) 
[1-5]. With extended life expectancy worldwide, patients suffering from 
these pathologies will increase in the coming years. 
Nowadays, symptomatic treatments exist, but there are currently no 
effective drugs to reverse or halt the progression of the diseases. Improving 
the early and predictive diagnosis of neurodegenerative diseases is the 
paramount importance and enormous efforts are under way [6-8].
Therefore, it is required a tool to aid physicians, epidemiologists, 
and scientists in the study of human diseases by confirming a diagnosis 
and tracking disease progression, which may help to identify specific 
therapeutic targets.
So, development of biomarkers may measure disease risk, presence, 
and progression is one of the main goals and challenges in research in 
neurodegenerative diseases [8,9]. 
For National Institutes of Health (NIH) a biomarker is “a 
characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention” (2001).
Advances in biochemistry (neurochemistry, proteomics, genomics) 
have increased our understanding of the central nervous system at the 
molecular level and applied us to screen for new biomarkers specific 
Biomarkers in Neurodegenerative Diseases: Cortisol 
Patrícia Batista1 and Anabela Pereira2*
1Aveiro University, Aveiro, Portugal
2Aveiro University, Aveiro, CINTESIS, CIDTFF, Portugal
Abstract
Neurodegenerative diseases are characterized by progressive loss of cognitive function, dementia, and problems 
with movements.
Identification of biomarkers during disease process, induce to an effective and early diagnostic test for 
neurodegenerative diseases. These biomarkers would allow presymptomatic disease detection of disease and 
would be valuable for monitoring the efficacy of disease.
Cortisol is a biomarker used for stress evaluation and a potential neurodegenerative disease biomarker.
Objective: The aim of this paper is to review systematically the scientific literature about evaluation to cortisol 
biomarker in neurodegenerative diseases.
Methods: Systematic literature review on Pubmed, Medline and Scopus database with the keywords "cortisol 
biomarkers” and "neurodegenerative diseases". It was analyzed all existing articles (between 1988 and 2015). 
PRISMA criteria reporting of systematic reviews and meta-analyses were applied. The inclusion criteria were: cortisol 
biomarkers in neurodegenerative diseases diagnosis, presenting quantitative or qualitative results. It was excluded 
articles outside the scope of the subject and articles with unavailable information.
Results: After applying the methodology, 14 scientific articles were included in the study. So, these studies were 
analyzed.
Conclusions: This paper review based on the contribution of cortisol biomarkers to diagnose and treat 
neurodegenerative diseases.
for neurodegenerative processes [1,10]. There is a need for additional 
and more sensitive biomarkers for the early and differential diagnosis 
of different neurodegenerative disease [6]. Identification of preclinical 
biomarkers for neurodegenerative diseases has led to new insights 
concerning disease pathophysiology and time course and has disclosed 
some interesting parallels in these common neurodegenerative diseases.
Body fluids, such as cerebrospinal fluid (CSF), serum, saliva, blood 
or urine, offer an attractive medium to biomarker analysis [5,10-15].
The firsts biochemical biomarkers of neurodegenerative diseases 
were: the proteins beta-amyloid (Aβ), total tau and its phosphorylated 
forms (p-tau) measured in cerebrospinal fluid (CSF), but, these markers 
are dependent upon invasive lumbar puncture and therefore appear less 
amenable for high through screening of patients [11,13,15]. There is a 
pressing need for new biomarkers in more easily accessible body fluids 
such as peripheral blood [6,8,13].
Nowadays, recent studies prove that blood-based testing would be 
widely available, non-invasive, easy, economic and rapid to perform. 
In this review, we analyzed the paper of cortisol biomarker in 
neurodegenerative disease.
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Cortisol is a steroid hormone and the most important human 
glucocorticoid, and regulates a variety of important cardiovascular, 
metabolic, immunological, homeostatic, and brain functions (brain 
metabolism, gene expression, and memory) [3,16-18]. Cortisol levels 
are known to increase within minutes of a stressful event, and high 
cortisol levels increase activity of the hypothalamus-pituitary-adrenal 
(HPA) axis [4,5,17,18].
Therefore, the aim of this paper is to systematically review 
the scientific literature about evaluation to cortisol biomarker in 
neurodegenerative diseases.
Methods
We conducted a study of reflective systematic literature review. 
Between 1998 and 2015, we identified scientific papers published in 
international journals, using a search of the databases in digital format, 
MedLine and PubMed, and a second phase to Scopus. The descriptors 
used in the research were: ["biomarkers” and “neurodegenerative 
diseases"]. Time later, because of the high number of matches (11843 
publications), the research was refined to ["cortisol biomarkers" and 
"neurodegenerative diseases”], having been obtained 34 publications. 
The study was restricted to English articles published. The research with 
the final descriptors ["cortisol biomarkers" and "neurodegenerative 
diseases"] resulted in 34 publications in PubMed database, 16 
publications in MedLine and 16 publications in Scopus. Analyzed 
34 publications obtained in the PubMed database, form excluded 20 
publications: 16 publications were outside the scope of the study and 4 
articles with unavailable information. 
The inclusion and exclusion criteria of the studies are described:
a)  Inclusion: cortisol biomarkers in neurodegenerative diseases 
diagnosis, presenting quantitative or qualitative results. 
b) Exclusion: other biomarkers in neurodegenerative diseases, no 
presenting quantitative or qualitative results and articles with 
unavailable information.
PRISMA criteria for preferred reporting items for systematic 
reviews and meta-analyzes (Prisma)ª were applied. The information 
collected was compiled and analyzed with respect to the year of 
publication, authors, sample and country, type of study/methodology, 
results and aim.
The cataloguing and identification of repeated references were made 
through the computer program EndNote bibliographic referencing 
(Figure 1).
Analysis of Results and Discussion
For a better understanding of the systematic literature review, 
studies analyzed were compiled in a summary table (Table 1). In this 
table there are several items: year of publication/authors, sample, 
country, methodology, instruments, results and aims.
It was analyzed fourteen complete articles which met the inclusion 
criteria.
A total of 4361 adults from four different countries (United States, 
Canada, Germany, Poland, Australia, France, Switzerland, Sweden and 
Japan) were analyzed. Different dimensions to evaluate biochemical 
parameters, physical, neurological and psychiatric dimensions. 
Similarly, many instruments were used to measure different dimensions 
were analyzed.
Cross-sectional and longitudinal studies methodologies were 
present in this review.
 
First Research Results
“ Biomarkers” AND “ Neurodegenerative diseases”
N=11843
Research Results
“Cortisol Biomarkers” AND “ Neurodegenerative diseases”
N=34
N=14
Articles analysed
N=20
Articles exclued
N=16
(outside the scope 
of the study)
N=4
(unavailable
information)
Figure 1: Flowchart - applying the inclusion and exclusion criteria in research.
Author/
Yearar Sample Country Methodology Instruments
Dimensions 
evaluated Results Aim
Popp et al., 
[5]
N= 289 (147 adults 
with mild cognitive 
impairment 
(MCI), 105 with 
ADdementia, 
37 controls with 
normal cognition)
Germany
Cross-sectional 
Longitudinal 
observational 
study
Consortium to 
Establish a Registry 
for Alzheimer’s 
Disease 
Neuropsychological 
test battery, Trail-
Making Tests A and 
B, Bayer Activities 
of Daily Living 
Scale, Clinical 
Dementia Rating 
Scale, magnetic 
resonance imaging
Clinical, 
Neuropsychological, 
Laboratory
- Increased baseline CSF 
cortisol levels in subjects 
with AD at the MCI stage are 
associated with faster cognitive 
decline and progression of 
dementia severity over time. 
- HPA-axis dysregulation occurs 
at the MCI stage of AD and may 
accelerate disease progression 
and cognitive decline.
To investigate whether 
HPA-axis dysregulation 
occurs at early clinical 
stages of AD and whether 
plasma and CSF cortisol 
levels are associated 
with clinical disease 
progression.
Gruber et 
al., [24]
N= 59 (6 
presymptomatic 
carriers of mutation 
conditioning HD, 
24 HD, 29 control)
Poland Preliminary studies
TANITA Body 
Fat Monitor/
Scale TBF-604, 
Blood sampling, 
Canonical 
Discriminant 
Analysis
Fat tissue, 
Muscle mass, 
Skin temperature, 
Biochemical profiles 
(metabolic state and 
protein metabolism)
- Concerning amino acid profile 
and biochemical markers, 
Canonical Discriminant Analysis 
detected a panel of variables 
(Ser, Asn, Gln, Orn, Pro, Arg, 
Met, Cit, Val, TSH, glucose, 
urea, creatinine clirens, total 
protein, cortisol, CRP). Asn 
and Ser were revealed in all 
statistical analyses and could 
be considered as potential 
plasma HD biomarkers
To determine the profile 
of the amino acids profile 
in plasma samples 
from HD patients and 
presymptomatic carriers, 
compared to healthy 
subjects. 
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Toledo et al., 
[20] 
N=818 adult 
subjects (396 
MCI,193 probable 
AD, 229 cognitively 
normal)
USA and 
Canada
Data were 
obtained from 
the Alzheimer’s 
Disease 
Neuroimaging 
Initiative (ADNI) 
database.
SPARE-AD 
(Spatial Pattern 
of Abnormality for 
Recognition of 
Early Alzheimer’s 
disease),  Cognitive 
Test,  Biomarker 
Collection and 
Analysis,  Magnetic 
resonance imaging 
(MRI) Processing 
and Analysis, 
Positron emission 
tomography (PET), 
Biological markers, 
Clinical and 
neuropsychological 
assessment
Morphological 
brain,  Blood-
based biochemical 
biomarkers
- Association between AD-
like patterns of brain atrophy, 
quantified by the SPARE-AD 
index, and plasma cortisol, 
CgA, IGFBP-2 and MIP-1a 
levels.
- Stress and insulin responses 
and cytokines associated with 
recruitment of inflammatory 
cells in MCI-AD are associated 
with its characteristic AD-like 
brain atrophy pattern and 
correlate with clinical changes 
or CSF biomarkers.
Relationship between 
a panel of plasma 
biomarkers and presence 
of AD-like brain atrophy 
patterns defined by a 
previously published 
index (SPARE-AD) at 
baseline in subjects of 
the ADNI cohort.  Test 
whether serial magnetic 
resonance imaging, 
positron emission 
tomography, other 
biological markers, 
and clinical and 
neuropsychological 
assessment can be 
combined to measure the 
progression of MCI and 
early AD.
Shirbin et 
al., [4]
N=59  (19 early-
HD, 20 pre-HD, 
and 20 HD CAG 
normal controls)
Australia Preliminary study
Wechsler Adult 
Reading (WTAR),  
Inventory of 
Depressive 
Symptomatology—
Self Report,  
Perceived
Stress Scale,
Pittsburgh Sleep 
Quality Index 
(PSQI),
California Verbal 
Learning Test,
Saliva collection
Assessment of 
learning and memory, 
Diagnostic status 
on salivary cortisol 
concentration.
- Suggest that dysregulation of 
cortisol concentrations may be 
involved in the decline of verbal 
learning and memory recall 
ability in HD (but no causal 
relationship).
- Not find relations between 
recognition memory 
performance and cortisol 
levels. - Cortisol neurotoxicity 
hypothesis (more relevant). 
Suggestive correlations 
showing that heightened stress 
was present in HD expansion 
carriers, and was related to 
evening salivary cortisol levels, 
as well as learning and memory 
performance.
Suggest hypercortisolism and 
the underlying pathological 
changes may begin many years 
before a clinical diagnosis is 
made, but the memory decline 
associated with HPA axis 
disturbance may only become 
detectable once motor signs 
become pronounced.
To identify whether there 
is an association between 
cortisol levels and verbal 
learning and memory in 
the early stages of HD.
Czech et al., 
[12] 
N= 130 (59 AD, 51 
healthy Controls)
Germany, 
France, 
Switzerland, 
Sweden
Cross-sectional
NINCDS-ADRDA 
and DSM IV 
criteria. MRI 
examination 
or PET, mass 
spectrometry 
analysis
Metabolite profiling
- Significant changes in the 
metabolite profile of AD patients 
compared to healthy controls 
have been identified. 
- Increased cortisol levels 
related to the progression of AD 
and detected AD.
-  Several combinations of three 
to five metabolites, including 
cortisol and various amino 
acids, in addition to cysteine 
and uridine.
To identify the metabolic 
changes resulting from 
the disease phenotype 
by a thorough and 
systematic metabolite 
profiling approach.
Doecke et 
al., [13] N=961  (754 health adult, 207 AD). Australia
Longitudinal 
Data where 
obtained from 
Australian 
Imaging 
Biomarker and 
Lifestyle study 
(AIBL) 
151-analyte 
multiplex 
panel (Human 
DiscoveryMAP, 
version 1.0; RBM)
Blood pathology 
testing
- Biomarker panel was identified 
in AD:
a) markers significantly 
increased (cortisol, pancreatic 
polypeptide, insulinlike growth 
factor binding protein 2, 
β2 microglobulin, vascular 
cell adhesion molecule 1, 
carcinoembryonic antigen, 
matrix metalloprotein 2, CD40, 
macrophage inflammatory 
protein 1α, superoxide 
dismutase, and homocysteine)
b) markers significantly 
decreased (apolipoprotein 
E, epidermal growth factor 
receptor, hemoglobin, calcium, 
zinc, interleukin 17, and 
albumin).
To identify plasma 
biomarkers for the 
diagnosis of AD.
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Roozendall 
et al., [3] N=29 ALS patients
Republic of 
Korea
Cross-sectional 
nature.
ALS functional 
rating scale 
(ALSFRS), Manual 
muscle test (MMT),  
Beck Depression 
Inventory 
(BDI), Hamilton 
Depression Rating 
Scale (HDRS)
Salivary cortisol 
collection and 
assay, Clinical and 
depressive status
- CAR was significantly 
smaller in ALS patients than in 
caregiver controls. 
- A smaller CAR in ALS patients 
was significantly correlated 
to poorer clinical status ( as 
assessed with both the ALSFRS 
and MMT rating instruments) 
and a more severe depressive 
mood status. 
- No correlations were observed 
between total cortisol outputs 
during the first 45 min post 
awakening and clinical or 
depressive status. 
Investigated whether 
the cortisol awakening 
response (CAR) of 
patients with ALS differed 
from that of a carefully 
selected group of age-
matched caregiver control 
subjects. Examined 
whether the magnitude of 
the CAR in ALS patients 
correlated with their 
clinical and/or depressive 
mood status.
Soares et 
al., [14]
N=566 (396 
mild cognitive 
impairment, 112 
AD, 58 healthy 
control)
USA and 
Canada Longitudinal
Alzheimer’s 
Disease 
Neuroimaging 
Initiative (ADNI) 
cohort
Plasma sample 
collection,  
Laboratory tests
- All participants with Apo ε3/
ε4 or ε4/ε4 alleles showed a 
distinct biochemical profile 
characterized by low C-reactive 
protein and ApoE levels and 
by high Cortisol, interleukin 13, 
apolipoprotein B, and gamma 
interferon levels. 
- Plasma biomarkers improved 
specificity in differentiating 
patients with AD from controls, 
and ApoE plasma levels were 
lowest in patients whose mild 
cognitive impairment had 
progressed to dementia. 
- Incorporation of plasma 
biomarkers yielded high 
sensitivity with improved 
specificity.
To apply a multiplex 
immunoassay panel 
to identify plasma 
biomarkers of AD using 
plasma samples from 
the Alzheimer’s Disease 
Neuroimaging Initiative 
cohort.
Toledo et al., 
2012
N= 819 adult 
subjects  (229 
cognitively 
normal  (CN), 398 
mild cognitive 
impairment (MCI), 
192 AD)
USA Cross-sectional
Pittsburgh 
Compound 
B-positron emission 
tomography (PiB-
PET) studies,  
Mini- Mental State 
Examination.
Physical and 
neurologic 
examinations, 
Standardized 
neuropsychological 
assessments, 
Biological samples 
(blood, urine, 
cerebrospinal fluid)
- Association between Aβ 
brain burden measured in vivo 
and diastolic blood pressure 
and cortisol, indicating a 
possible link between these 
cardiovascular risk factors and 
Aβ burden measured by PiB-
PET.
Relationship between 
body mass index, systolic 
blood pressure, diastolic 
blood pressure, altered 
fasting glucose, plasma 
levels of cortisol, acute-
phase proteins, and 
amyloid-β (Aβ) burden, as 
measured by Pittsburgh 
Compound B-positron 
emission tomography 
(PiB-PET) studies.
Laske et al., 
[18]
N= 310 (170 
AD, 140 healthy 
controls) 
Gemany Longitudinal
Mini-Mental State 
Examination 
(MMSE)
Blood sampling
- Identified a panel of three 
blood markers, which allowed 
support vector machine (SVM)-
based distinguishing of AD 
patients from healthy controls.
- Blood-based biomarkers might 
have utility in AD diagnostics. 
To determine whether 
multivariate data analysis 
(with use of SVM) of a 
blood-based biomarker 
panel allows discrimination 
between AD patients and 
healthy controls at the 
individual level.
Laske et al., 
[18] N=46  (26 AD, 20 healthy controls) Gemany Cross-section
ICD-10,  DSM-IV, 
National Institute 
of neurologic and 
communicative 
disorders and 
stroke and the 
Alzheimer’s 
disease and 
related disorders 
association 
association 
(NINCDS-ADRDA)
Serum collection,  
Physical,  
Neurological, 
and Psychiatric 
examination.
- Higher cortisol serum but not 
CSF levels are associated with 
minor signs of AD pathology.
- Neuroprotective effect of 
moderately elevated cortisol 
serum levels in patients with 
mild AD dementia.
Measure cortisol levels 
(both in serum and CSF), 
in patients with mild AD 
dementia. Evaluate their 
correlation with biomarker 
levels of AD in CSF to 
assess the association of 
cortisol with AD pathology. 
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Popp et al., 
[17]
N=133 subjects 
(66 AD, 33 with 
mild cognitive 
impairment 
(MCI) and 34 
cognitively normal 
participants). 
Germany Longitudinal 
Cognitive Testing, 
Biomarker 
Collection and 
Analysis, MRI 
Processing and 
Analysis
Diagnostic lumbar 
punctures; Serum 
cortisol RIA
- Higher CSF cortisol levels 
in AD compared to control 
subjects after controlling for the 
APOE genotype effect. 
-  Normal cortisol level in 
MCI subjects compared to 
cognitively healthy controls. 
- Several AD related biological 
alterations, hippocampal 
atrophy and reduced glucose 
metabolism, and CSF 
biomarker changes occur early 
in the course of AD and can be 
demonstrate already in subjects 
with MCI.
- Not known, whether HPA axis 
dysfunction also occurs in pre-
dementia AD. 
- CSF cortisol concentrations in 
MCI and in cognitively healthy 
controls indicates that a marked 
cortisol increase does not arise 
early in AD.
To investigate whether 
CSF cortisol levels 
are elevated in AD. To 
determine if the increase 
of CSF cortisol represents 
an early event in the 
course of AD and can be 
detected already in MCI.
Umegaki et 
al., [23] 
N=115 (66 AD, 
28 with vascular 
dementia and 21 
non-demented 
controls). 
Japan
Cross-sectional 
findings of 
cortisol profiles
Mini-Mental State 
Examination
Basal plasma 
cortisol levels, 
Radioimmunoassay
- AD and vascular dementia 
subjects had higher levels 
of plasma cortisol than ND 
subjects.
- Cortisol levels in AD subjects 
did not change significantly.
- In AD subjects in relatively 
early stages of the disease who 
had higher cortisol levels, an 
accelerated progression of the 
disease was observed.
To investigate the plasma 
cortisol levels at a fasting 
state in elderly female 
Alzheimer’s disease 
(AD), vascular dementia 
(VD), and non-demented 
subjects.
Miller et al., 
[16]
N=27 patients 
with diagnosis of 
probable AD
California Longitudinal
Alzheimer’s 
disease 
assessment scale
Complete medical, 
psychiatric, 
neurologic, 
neuroimaging and 
neuropsychological 
assessment
- Cortisol and 
dehydroepiandrosterone 
(DHEA) were determined using 
conventional radioimmunoassay 
procedures.
- Not document relationship 
between cortisol or DHEA levels 
and non-cognitive measures. 
- Significant correlation between 
both the initial MMSE and 
ADAS cognitive measures and 
initial DHEA level, with lower 
DHEA levels unexpectedly 
being associated with better 
performance on these 
measures. 
- potential usefulness of DHEA 
as a therapeutic agent.
To investigate the 
relationship between 
basal cortisol and 
dehydroepiandrosterone 
levels and impairment 
in different cognitive 
and non-cognitive 
measures and the 
possible interaction of 
dehydroepiandrosterone 
with hypercortisolemia in 
dementia.
Table 1: Summary of information from fourteen relevant articles met our inclusion criteria in the study of “Cortisol biomarkers and neurodegenerative diseases”.
The current review revealed many studies about biomarkers in 
neurodegenerative diseases, but few studies about "Cortisol biomarkers 
in Neurodegenerative diseases”.
Development of biomarkers that may measure disease risk, 
presence, and progression is one of the main goals and challenges in 
research in neurodegenerative diseases.
The availability of neuroimaging and biomolecular biomarkers to 
monitor and control brain changes structures, inflammatory processes 
and other biochemical pathways enable investigation of pathways that 
may be related to neurodegenerative disease [5,19,20].
Biomarkers for these pathologies are of great value as diagnostic 
aids (especially early in the course of the disease, when the clinical 
symptoms are vague and diagnosis are difficult), therefore, these 
biomarkers should reflect the central pathogenic processes of the 
diseases. 
Laske et al., identified three blood markers, involved in 
several biological pathways including cardiovascular, metabolic, 
immunological, homeostatic, and brain functions (cortisol), oxidative 
stress and antioxidant response (OLAB), and endothelial dysfunction 
(vWF), which have been associated with the pathogenesis of AD [18]. 
Soares describe a list of biomarkers identified within the Alzheimer 
Disease Neuroimaging Initiative (ADNI) cohort and Doecke present 
biomarkers identified (cortisol, IGFBP2, and PPY) within the Australian 
Imaging, Biomarkers and Lifestyle (AIBL) study [13,14]. These data 
indicate that further research validating cortisol levels across different 
neurologic diseases is required to determine its specificity [13].
Other studies about cortisol, indicate that it might independently 
cause brain atrophy and the increase (peripheral and central) of the 
nervous system cortisol levels have been reported in neurodegenerative 
diseases (Alzheimer’s disease) and may reflect dysfunction of cerebral 
components of the hypothalamic-pituitary-adrenal (HPA) axis 
[5,15,20]. Most studies focusing on HPA axis and cortisol in patients 
with AD have measured plasma, CSF or salivary cortisol levels, but, 
Citation: Batista P, Pereira A (2016) Biomarkers in Neurodegenerative Diseases: Cortisol. J Mol Biomark Diagn 7: 277. doi:10.4172/2155-9929.1000277
Page 6 of 7
Volume 7 • Issue 2 • 1000277
J Mol Biomark Diagn
ISSN:2155-9929 JMBD an open access journal 
Biomarkers Discovery & Validation
in humans, only a few observational studies have investigated whether 
increased salivary or plasma cortisol levels predict a more rapid disease 
progression in AD, reporting inconclusive results [5,14,21,22].
The HPA axis is a neuroendocrinological system that regulates the 
circulation of cortisol concentration in response to psychological and 
physical stress. It is implicated in a number of physiological pathways 
and functions including the sleep wake cycle, mood, cognition, energy 
storage and metabolism, digestion, sexual behaviour, and the immune 
system; many of which are disturbed in HD. HPA axis abnormalities 
and heightened cortisol levels have been identified in HD [4]. HPA 
axis hyperactivity with increased cortisol levels may be not only an 
early event in the course of AD but also a factor precipitating cognitive 
decline and clinical worsening over time. Nevertheless, the role of 
hypercortisolism in the pathogenesis and progression of AD remains 
a subject of controversy.
However, brain exposure to high cortisol concentrations may 
also accelerate disease progression, pathophysiological process, and 
accelerate clinical disease progression [5].
Elevated cortisol levels have also been associated with reduced 
learning and memory abilities in normal aging [4]. Shirbin suggest that 
dysregulation of cortisol concentrations may be involved in the decline 
of verbal learning and memory recall ability in patients with HD, 
but did not find relations between recognition memory performance 
and cortisol levels [4]. The verbal learning and memory deficits 
identified in this study may be related to hippocampal dysfunction 
due to abnormally high cortisol levels that is similar to the profile of 
other disorders that also display abnormal hippocampal morphology 
associated with dysregulated HPA axis activity, such as AD and major 
depressive disorder [4,12,17,23].
These study suggest HPA axis hyperactivity may begin in the pre-
HD stage with a prolonged period of hypercortisolism damaging the 
hippocampus, and functional learning and memory deficits might 
only become evident after transitioning to the early-HD stage and 
unequivocal HD motor signs are displayed [4]. Also, hypothalamic 
pathology in pre-HD and HD patients suggests that the hypothalamus 
is a plausible root cause of abnormal cortisol concentrations (especially 
higher cortisol levels) [4].
Shirbin et al. mentioned the cortisol neurotoxicity hypothesis, 
hippocampus induces a continuum cycle of dysregulated high cortisol 
levels and ongoing hippocampal degeneration [4]. High stress may be 
influence toxic effect, as observed in other studies which have indicated 
associations between prolonged stress, high cortisol, hippocampal damage, 
and learning and memory deficits [4]. This study was the first to report the 
utility of cortisol levels as a biomarker of cognitive decline in HD [4].
Also, Gruber et al. analyzed some parameters in the plasma samples 
which may potentially discriminate controls and HD patients [24]. 
Concerning amino acid profile and biochemical markers, Canonical 
Discriminant Analysis detected a panel of variables (Ser, Asn, Gln, 
Orn, Pro, Arg, Met, Cit, Val, TSH, glucose, urea, creatinine clirens, 
total protein, cortisol, CRP). Asn and Ser were revealed in all statistical 
analyses and could be considered as a potential plasma HD biomarkers, 
but more search is needed for HD plasma biomarkers [24].
Other studies mentioned that the increased plasma levels of cortisol 
and C-reactive protein prove increased anxiety, stress, depression and 
inflammatory component in the symptoms reported in HD [24]. 
Likewise, cortisol was correlated with clinical status and depressive 
mood in ALS patients [3]. 
The cortisol awakening response in ALS is blunted, and Roozendaal 
et al. analyze this problem [3]. They concluded, as previous findings 
indicates, that particularly the rise in cortisol levels immediately after 
awakening, the cortisol awakening response (CAR), is associated with 
indices of physical and emotional well-being. Their data indicates that 
ALS patients show a blunted CAR, correlated with disease (poorer 
clinical status) and severe depressive status. Thus, ALS patients may 
be a consequence of the emotional or physical distress and associated 
symptoms of chronic fatigue and depression. These results suggest a 
reduced responsivity of the HPA-axis in ALS [3].
Beyond the depression, epidemiological evidence that 
cardiovascular risk factors (CVRF) are risk factors for Alzheimer’s 
disease, but there is limited information on this from neuropathological 
studies. Cortisol has been related to Aβ deposition and memory deficits 
in normal transgenic mice and to hippocampal atrophy in human brain 
magnetic resonance imaging studies [15]. Therefore, we examined 
the relationship between CVRF and amyloid-β (Aβ) brain burden 
measured by Pittsburgh Compound B-positron emission tomography 
(PiB-PET) studies in the Alzheimer’s Disease Neuroimaging Initiative 
[15]. This study confirms the relation between cortisol and brain Aβ 
deposition in human subjects [15].
Summary of Methodological Limitations
Numerous articles have been developed in the field of biomarkers 
to the application in neurodegenerative diseases, and search was more 
restricted.
The selected biomarker can´t be the one with the most reliable 
results and making the limited study.
The use of a single measuring instrument, would have allowed an 
easier and more correct comparison of the identified variables. 
We found limitations in the analyzed articles: small number the 
subjects [4,11,24]; longer follow-up in larger samples of participants 
[5]; difficult to be precise about the interdependence of the parameters 
[24]; allowing more detailed consideration for the impact of stress, [4]; 
difficulties in longitudinal epidemiological studies is to discern the 
underlying pathology or pathologies [15]; small longitudinal studies 
[14]; little salivary cortisol collections [3], diurnal variability in cortisol 
levels [18].
Implications for Practice
Neurodegenerative disorders are a heterogeneous group of disorders 
characterized by a progressive and selective loss of anatomically or 
physiologically related neuronal systems that is affecting people of all 
ages (affects older and some young adults). Although in these diseases, 
the mechanisms are still far from being clarified. Future studies are 
needed to investigate the neurological or psychological mechanisms 
underlying this alteration in HPA responsivity.
In recent years, there has been a growing interest in applying biomarkers 
to research on prognosis and treatment of neurodegenerative diseases.
This literature review, suggest new studies about biomarkers in 
neurodegenerative diseases.
More studies are important to understand the mechanism and 
actuation of biomarkers in diagnosis and treatment of these diseases.
Conclusion
Neurodegenerative diseases are a growing problem worldwide, 
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given the rapidly ageing population, the current search for biomarkers 
is very important.
Biomarkers for neurodegenerative diseases should reflect the 
central pathogenic processes of the diseases (for example, neuronal 
degeneration).
There is an urgent need for biomarkers to diagnose 
neurodegenerative diseases early in their course, to differentiate them 
from other related diseases or subtypes, and to monitor responses of 
patients to new therapies.
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